Microglial activation associated with a faster progression of nigrostriatal dysfunction in patients with isolated REM sleep behavior disorder
Objective: To assess the role of early microglial activation on the progression of nigrostriatal dysfunction, measured with 18F-DOPA PET, in isolated REM sleep behavior disorder…Lack of depotentiation may not be a hallmark of Levodopa-induced dyskinesias
Objective: Paired associative stimumlation (PAS)-induced plasticity, a form of spike-time dependent plasticity (STDP), is deficient in PD. We tested whether (1) PAS-induced plasticity could be…Value of nocturnal hypokinesia screening concerning the quality of life and clinical features in Parkinson’s disease
Objective: To assess nocturnal hypokinesia and its relationship with clinical features and quality of life (QoL) in patients with Parkinson’s disease (PD). Background: The nocturnal…Trajectories of pain in newly diagnosed Parkinson’s disease
Objective: To determine the frequency and stability of pain over time in a cohort of patients with early Parkinson’s disease (PD). Background: Pain is a…Association between essential tremor, constipation, and the risk of developing Parkinson’s disease
Objective: To evaluate the association between constipation and the risk of Parkinson’s disease (PD) in patients with a prior history of essential tremor (ET). Background:…Movement Disorders After Bariatric Surgeries – Case Series
Objective: Our objective is to report 6 cases series of MD after Bariatric surgeries (BS) and one case after hiatal surgery, with BS behavior. Background:…Attitudes of Care Partners Toward Medications for Parkinson’s Disease Psychosis
Objective: To explore attitudes regarding use of medications among care partners of individuals with Parkinson’s disease psychosis. Background: Parkinson’s disease (PD) psychosis is a highly…CVT-301 treatment provides consistent and clinically significant improvements in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) over 12 weeks
Objective: A post hoc analysis of UPDRS-III sequential changes over the 12-week treatment period of a phase 3 study. Background: CVT-301 is an inhaled levodopa…Parkinson Progression Marker Initiative 2.0 – New Science/New Cohorts
Objective: The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes,…Phase I Study Design of a Leucine-Rich Repeat Kinase 2 (LRRK2) Antisense Oligonucleotide, for Parkinson’s Disease
Objective: We will present the preclinical efficacy and safety data and the design of the first in human trial of an antisense oligonucleotide (ASO) for…
- « Previous Page
- 1
- …
- 83
- 84
- 85
- 86
- 87
- …
- 388
- Next Page »